Business Context and Reporting Period
This Form 8-K filing by NanoViricides, Inc. (NNVC) reports on events occurring on March 16, 2020, with the report dated March 20, 2020. The company is incorporated in Nevada and trades on the NYSE-American. The filing primarily addresses a Special Meeting of Stockholders held to approve amendments to the company's Articles of Incorporation.
Key Financial Metrics
This filing is a current report regarding corporate governance and capital structure changes. It does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. No financial statements are included in this document.
Material Changes
The material change reported is a significant increase in the company's authorized capital stock, approved by stockholders on March 16, 2020, and filed with the State of Nevada on March 19, 2020:
- Total Authorized Shares: Increased from 8,000,000 to 160,000,000.
- Common Stock: Increased from 7,500,000 to 150,000,000 shares (par value $0.001).
- Preferred Stock: Increased from 500,000 to 10,000,000 shares of "blank check" preferred stock (par value $0.001).
Voting Results and Management Commentary
At the Special Meeting, a quorum was established with 5,114,594 votes present out of 7,152,067 entitled to vote. The voting results for the amendment proposal were:
- Votes For: 4,088,014
- Votes Against: 1,013,474
- Votes Abstained: 13,105
A second proposal to adjourn the meeting for further proxy solicitation was rendered moot once a quorum was reached. The filing does not provide specific management commentary on future outlook, risks, or contingencies beyond the procedural details of the stockholder vote.
Investor Verification Checklist
- Verify the impact of the 10x increase in authorized common stock on potential future dilution.
- Review the terms of the newly authorized 10,000,000 shares of "blank check" preferred stock to understand potential rights and preferences.
- Consult the Definitive Proxy Statement filed on February 19, 2020, for the detailed rationale behind the capital structure amendment.
- Note that this filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.